Tested Applications
| Positive WB detected in | mouse brain tissue, C6 cells, human brain tissue |
| Positive IF/ICC detected in | C6 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
14071-1-AP targets Nicastrin in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag5137 Product name: Recombinant human Nicastrin protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 338-689 aa of BC047621 Sequence: NVDSFVELGQVALRTSLELWMHTDPVSQKNESVRNQVEDLLATLEKSGAGVPAVILRRPNQSQPLPPSSLQRFLRARNISGVVLADHSGAFHNKYYQSIYDTAENINVSYPEWLSPEEDLNFVTDTAKALADVATVLGRALYELAGGTNFSDTVQADPQTVTRLLYGFLIKANNSWFQSILRQDLRSYLGDGPLQHYIAVSSPTNTTYVVQYALANLTGTVVNLTREQCQDPSKVPSENKDLYEYSWVQGPLHSNETDRLPRCVRSTARLARALSPAFELSQWSSTEYSTWTESRWKDIHARIFLIASKELELITLTVGFGILIFSLIVTYCINAKADVLFIAPREPGAVSY Predict reactive species |
| Full Name | nicastrin |
| Calculated Molecular Weight | 709 aa, 78.4 kDa |
| Observed Molecular Weight | 110 kDa |
| GenBank Accession Number | BC047621 |
| Gene Symbol | Nicastrin |
| Gene ID (NCBI) | 23385 |
| RRID | AB_2149583 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q92542 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Nicastrin (NCT) is a type I transmembrane glycoprotein, which forms high molecular weight gamma-secretase complexes with with presenilin 1 and presenilin 2 (PMID: 16096051). The gamma-secretase is an intramembrane protease cleaves many type I membrane proteins including amyloid precursor protein (APP) and Notch, generating peptide fragments that are important signaling components (PMID: 16096062). The proteolytical processing of APP results in the release of amyloid-βpeptide, a principal component of the plaques found in the brains of Alzheimer's disease patients (PMID: 12716934).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for Nicastrin antibody 14071-1-AP | Download protocol |
| WB protocol for Nicastrin antibody 14071-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Nicastrin polyclonal antibody (Cat# 14071-1-AP) has 8 total citations published in Gut Microbes, J Neuroinflammation, Aging Cell, Cancer Cell Int, Mol Neurobiol, Front Oncol, Neurosci Lett, and Heliyon. Research fields span Alzheimer's disease pathogenesis and Aβ clearance, cerebral amyloid angiopathy, hepatocellular carcinoma, metformin therapeutic response, and moyamoya disease biomarker identification.
| Species | Application | Title |
|---|---|---|
Gut Microbes Gut-derived β-amyloid: Likely a centerpiece of the gut-brain axis contributing to Alzheimer's pathogenesis | ||
J Neuroinflammation Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer's disease-like mice. | ||
Aging Cell Myeloid ectopic viral integration site 2 accelerates the progression of Alzheimer's disease | ||
Cancer Cell Int Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation.
| ||
Mol Neurobiol Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression. | ||
Front Oncol Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner. |







